20 mg/g, gel
O-(β-hydroxyethyl)-rutoside (Oxerutins)
You should carefully read the contents of the leaflet before using the medicine, as it contains
information important for the patient.
This medicine should always be used exactly as described in the patient leaflet or as advised by
your doctor or pharmacist.
Venoruton Gel belongs to a group of medicines that protect the veins.
Venoruton Gel works on the smallest blood vessels (capillaries) by reducing the permeability of damaged capillary walls to fluids and morphotic blood elements.
The medicine is indicated for local application to the skin in pains and swellings of the legs caused by chronic venous insufficiency and its symptoms, such as: feeling of "heavy legs" and pains in the lower limbs, swelling of the lower limbs, muscle cramps, and sensory disturbances.
It is used in painful conditions after obliterative treatment of varicose veins.
If you are allergic to the active substance or to any of the other ingredients of this medicine (listed in section 6).
Due to the presence of benzalkonium chloride, the medicinal product may cause skin irritation.
1 of 3
You should tell your doctor or pharmacist about all the medicines you are taking or have recently taken, as well as any medicines you plan to take.
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, you should consult your doctor or pharmacist before using this medicine.
No effect on the ability to drive and use machines.
Venoruton Gel should be applied in the morning and evening to the affected area, gently rubbing until the skin is dry.
Venoruton Gel can be used under an elastic bandage or occlusive dressing.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Some side effects are rare(may affect up to 1 in 1,000 people).
Rare cases of allergic reactions with skin reactions have been observed.
All symptoms disappear after discontinuation of the medicine.
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in the leaflet. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl.
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep the medicine out of the sight and reach of children.
Do not store above 25°C.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month stated.
Shelf life after first opening the tube – 3 months.
Medicines should not be disposed of via wastewater or household waste. You should ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
2 of 3
The active substance of Venoruton Gel is O-(β-hydroxyethyl)-rutoside.
1 g of gel contains 20 mg of O-(β-hydroxyethyl)-rutoside.
The other ingredients are: carbomer, sodium hydroxide, disodium edetate, benzalkonium chloride 0.05 mg/g, purified water.
The medicine is available in an aluminum tube with a lacquered interior containing 40 g of gel, placed in a cardboard box.
To obtain more detailed information, you should contact the marketing authorization holder or the parallel importer.
STADA Arzneimittel GmbH
1190 Vienna
Austria
STADA Arzneimittel GmbH
1190 Vienna
Austria
InPharm Sp. z o.o.
Strumykowa 28/11 Street
03-138 Warsaw
InPharm Sp. z o.o. Services sp. k.
Chełmżyńska 249 Street
04-458 Warsaw
Austrian marketing authorization number, country of export:15559
Parallel import authorization number:29/12
Date of leaflet approval: 20.01.2022
[Information about the trademark]
3 of 3
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.